INVESTORS & MEDIA
News Release
Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018
Conference Call Information
To access this call, dial (800) 708-4540 (
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information: |
|
Investor Relations |
Corporate Communications |
|
|
914.847.5126 |
914.847.3422 |
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-first-quarter-2018-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-3-2018-300625737.html
SOURCE
News Provided by Acquire Media